DK3773595T3 - Farmaceutiske anticancer-sammensætninger til kombineret terapi - Google Patents

Farmaceutiske anticancer-sammensætninger til kombineret terapi Download PDF

Info

Publication number
DK3773595T3
DK3773595T3 DK19721103.0T DK19721103T DK3773595T3 DK 3773595 T3 DK3773595 T3 DK 3773595T3 DK 19721103 T DK19721103 T DK 19721103T DK 3773595 T3 DK3773595 T3 DK 3773595T3
Authority
DK
Denmark
Prior art keywords
combination therapy
anticancer compositions
pharmaceutical anticancer
pharmaceutical
compositions
Prior art date
Application number
DK19721103.0T
Other languages
English (en)
Inventor
Giuseppe Merlino
Mario Bigioni
Monica Binaschi
Andrea Pellacani
Original Assignee
Berlin Chemie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berlin Chemie Ag filed Critical Berlin Chemie Ag
Application granted granted Critical
Publication of DK3773595T3 publication Critical patent/DK3773595T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK19721103.0T 2018-03-29 2019-03-28 Farmaceutiske anticancer-sammensætninger til kombineret terapi DK3773595T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102018000004082A IT201800004082A1 (it) 2018-03-29 2018-03-29 Composizioni farmaceutiche antitumorali per terapia combinata
PCT/IB2019/052541 WO2019186451A1 (en) 2018-03-29 2019-03-28 Anticancer pharmaceutical compositions for combined therapy

Publications (1)

Publication Number Publication Date
DK3773595T3 true DK3773595T3 (da) 2023-09-18

Family

ID=62875088

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19721103.0T DK3773595T3 (da) 2018-03-29 2019-03-28 Farmaceutiske anticancer-sammensætninger til kombineret terapi

Country Status (29)

Country Link
US (1) US20210015826A1 (da)
EP (1) EP3773595B1 (da)
JP (1) JP7460596B2 (da)
KR (1) KR102681847B1 (da)
CN (1) CN111918656B (da)
AU (1) AU2019244793B2 (da)
BR (1) BR112020019712A2 (da)
CL (1) CL2020002424A1 (da)
DK (1) DK3773595T3 (da)
EA (1) EA202092008A1 (da)
ES (1) ES2954502T3 (da)
FI (1) FI3773595T3 (da)
HR (1) HRP20231131T1 (da)
HU (1) HUE063047T2 (da)
IL (1) IL277649B2 (da)
IT (1) IT201800004082A1 (da)
LT (1) LT3773595T (da)
MX (1) MX2020010084A (da)
PH (1) PH12020551583A1 (da)
PL (1) PL3773595T3 (da)
PT (1) PT3773595T (da)
RS (1) RS64639B1 (da)
RU (1) RU2020131376A (da)
SG (1) SG11202009483YA (da)
SI (1) SI3773595T1 (da)
SM (1) SMT202300325T1 (da)
TW (1) TWI816768B (da)
UA (1) UA127288C2 (da)
WO (1) WO2019186451A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113368114B (zh) * 2020-03-10 2022-04-22 四川大学 一种吗啉嘧啶类化合物的抗肿瘤应用
AU2021408129A1 (en) * 2020-12-22 2023-07-13 Novartis Ag Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor for the treatment of cancers
CN115040523A (zh) * 2021-03-09 2022-09-13 上海翰森生物医药科技有限公司 Pi3k抑制剂联合雌激素受体拮抗剂在治疗肿瘤疾病中的用途
WO2024023766A1 (en) * 2022-07-28 2024-02-01 Berlin-Chemie Ag P13k inhibitor combination therapy
CN119074887B (zh) * 2024-07-31 2025-01-28 中国医学科学院医药生物技术研究所 一种治疗肿瘤的综合靶向药物复合物及其制剂和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3042964A1 (en) * 2004-06-04 2016-07-13 Genentech, Inc. Egfr mutations
TW200938201A (en) * 2008-02-07 2009-09-16 Chugai Pharmaceutical Co Ltd Pyrrolopyrimidine derivative as PI3K inhibitor and use thereof
CN103221052A (zh) * 2010-09-16 2013-07-24 施摩达生物技术有限公司 氟维司群组合物及使用方法
WO2012118978A1 (en) * 2011-03-03 2012-09-07 The Regents Of The University Of Colorado, A Body Corporate Methods for treating oncovirus positive cancers
US20130123255A1 (en) * 2011-11-10 2013-05-16 Chugai Seiyaku Kabushiki Kaisha Combination of a pi3k inhibitor and a mek inhibitor
WO2014115859A2 (ja) * 2013-01-25 2014-07-31 オンコリスバイオファーマ株式会社 分子標的併用腫瘍治療・予防薬
KR20220123335A (ko) * 2013-03-13 2022-09-06 온코슈틱스 인코포레이티드 7-벤질-10-(2-메틸벤질)-2,6,7,8,9,10-헥사하이드로이미다조[1,2-a]피리도[4,3-d]피리미딘-5(3h)-온과의 조합 치료요법
WO2014203129A1 (en) * 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
WO2015069217A1 (en) * 2013-11-05 2015-05-14 Baylor College Of Medicine Src kinase inhibition as treatment for lympangioleiomyomatosis and tuberous sclerosis
WO2015095807A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of egfr and erk inhibitors
FR3033499A1 (fr) * 2015-03-11 2016-09-16 Centre Leon-Berard Composition pour le traitement des tumeurs neuroendocrines pancreatiques
WO2016193955A1 (en) * 2015-06-04 2016-12-08 Giorgio Stassi Combinations of kinase inhibitors for treating colorectal cancer

Also Published As

Publication number Publication date
AU2019244793A1 (en) 2020-10-08
IL277649B1 (en) 2024-08-01
IT201800004082A1 (it) 2019-09-29
FI3773595T3 (fi) 2023-09-01
UA127288C2 (uk) 2023-07-12
AU2019244793B2 (en) 2024-06-13
WO2019186451A1 (en) 2019-10-03
KR20200138294A (ko) 2020-12-09
EP3773595B1 (en) 2023-07-12
LT3773595T (lt) 2023-09-25
RS64639B1 (sr) 2023-10-31
IL277649B2 (en) 2024-12-01
CL2020002424A1 (es) 2021-03-12
JP2021519821A (ja) 2021-08-12
ES2954502T3 (es) 2023-11-22
PH12020551583A1 (en) 2021-09-13
TWI816768B (zh) 2023-10-01
RU2020131376A (ru) 2022-04-29
BR112020019712A2 (pt) 2021-02-09
JP7460596B2 (ja) 2024-04-02
CN111918656A (zh) 2020-11-10
PL3773595T3 (pl) 2023-11-27
SG11202009483YA (en) 2020-10-29
SI3773595T1 (sl) 2023-11-30
IL277649A (en) 2020-11-30
MX2020010084A (es) 2021-01-15
CN111918656B (zh) 2023-08-08
EP3773595A1 (en) 2021-02-17
HRP20231131T1 (hr) 2024-01-05
EA202092008A1 (ru) 2021-01-18
KR102681847B1 (ko) 2024-07-04
TW202002984A (zh) 2020-01-16
SMT202300325T1 (it) 2023-11-13
US20210015826A1 (en) 2021-01-21
PT3773595T (pt) 2023-09-07
HUE063047T2 (hu) 2023-12-28

Similar Documents

Publication Publication Date Title
IL290823A (en) Pharmaceutical compositions for combination therapy
ZA201906613B (en) Pharmaceutical compositions for combination therapy
DK3616720T3 (da) Farmaceutisk sammensætning til cancerbehandling
IL268316B (en) Pharmaceutical preparations for combined treatment
ZA201905510B (en) Pharmaceutical compositions for combination therapy
DK3236943T3 (da) Sammensætninger til ileo-jejunal lægemiddeladministration
EP3641771A4 (en) PHARMACEUTICAL COMPOSITIONS
IL277649A (en) Preparations for the treatment of cancer by combining active substances
GB201804548D0 (en) Pharmaceutical compositions
MA47516A (fr) Composition pharmaceutique
MA49837A (fr) Compositions pharmaceutiques
EP3646866A4 (en) PHARMACEUTICAL PREPARATION
EP3646867A4 (en) PHARMACEUTICAL COMPOSITION
EP3646863A4 (en) PHARMACEUTICAL COMPOSITION
GB201808571D0 (en) Pharmaceutical compositions
GB201808567D0 (en) Pharmaceutical compositions
ZA202000014B (en) Pharmaceutical compositions
EP3616722A4 (en) PHARMACEUTICAL COMPOSITION
EP3423041A4 (en) PHARMACEUTICAL COMPOSITIONS
EP3528818A4 (en) PHARMACEUTICAL COMPOSITIONS
DK2952207T3 (da) Oliebaserede farmaceutiske sammensætninger til oral indgivelse
EP3880190A4 (en) ANTI-CANCER COMPOSITION
MA49625A (fr) Compositions pharmaceutiques
EP3854405A4 (en) ANTI-CANCER COMPOSITION
HK40013349A (en) Pharmaceutical compositions for combination therapy